Cambridge Healthtech Institute’s Second Annual 

Genomic Sample Prep and Biospecimen Science

Assuring Development of Robust and Accurate Omics Assays

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference


Personalized medicine is based on the analysis of inter-patient differences at the molecular level through the measurement of biomarkers. Biomarkers are detected in human biospecimens that represent samples for particular molecular tests. A systematic approach is necessary for quality assessment of biospecimens as well as for their appropriate pre-analytical processing both in research and in clinical laboratory. Novel genomic sample preparation technologies have the ability to significantly increase sensitivity and specificity of a test that is run on a heterogeneous sample or a sample that contains a low concentration of analyte. Cambridge Healthtech Institute’s Second Annual Genomic Sample Prep and Biospecimen Science conference is designed to bring together leading industry and academia experts in biospecimen science and molecular diagnostics to discuss major challenges and latest advances in sample preparation for advanced genomic technologies as well as biospecimen management and quality assurance.


Talk Title to Be Announced

Ronald W. Davis, Ph.D., Professor of Biochemistry and Genetics, Director, Stanford Genome Technology Center, Stanford University

Prea-Analytical Variation in Human Biospecimens: The Ultimate “Sample Preparation” Challenge for Diagnostics

Carolyn Compton, M.D., Ph.D., Professor, School of Life Sciences, Arizona State University

BioSpecimen Sciences at the Helm: The Next Generation of Specimen-Centered Clinical Trials Drive Personalized Health Care

Michael H.A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University of Toronto

Comparison of Various Preanalytical Strategies in Molecular Testing for Infectious Diseases

David R. Hillyard, M.D., Medical Director, Molecular Infectious Diseases, Arup Laboratories

SiemensStandardizing Molecular Pathology with Fully Automated Nucleic Acid Isolation from FFPE and FF Tissue Sponsored by Siemens

Guido Hennig, Ph.D., Senior Global Scientific Affairs Manager, BU Molecular Global Marketing, Siemens Healthcare Diagnostics


Validation Challenges for Panels and Exomes

Josh Deignan, Ph.D., Associate Director, UCLA Molecular Diagnostics Laboratories, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA

FDA-Approved Versus LDT – Based NGS Panels: Preanalytical Issues and Validation

Jamie L Platt, Ph.D., Vice President, Genomic Solutions, Molecular Pathology Laboratory Network, Inc.

Development and Validation of Clinical NGS tests: Tthe Requirements and the Challenges Presented by the Various Clinical Applications

Martin Siaw, Ph.D., Associate Scientific Director, Advanced Sequencing, Quest Diagnostics Nichols Institute

A Microfluidic DNA Llibrary Preparation Platform for Next-Generation Sequencing

Kamlesh Patel, Ph.D., Manager, Advance Systems Engineering and Deployment, Sandia National Labs

Circulating RNA - Is it a Blessing or a Curse?

Kai Wang, Ph.D., Principle Scientists, Institute of Systems Biology

RNAssist: A Novel Tissue Fixative for IHC Detection and Recovery of High Quality RNA, DNA and Proteins

Andrew Goldsborough, Ph.D., CEO, RNA stability, RNAssist Ltd

Panel Discussion: Analyzing and Comparing Major NGS Instruments

Moderator: Jamie L Platt, Ph.D., Vice President, Genomic Solutions, Molecular Pathology Laboratory Network, Inc.


Preparing Research Samples for Future Use: Innovative Methods for Assessing Functional Quality Control and Biobanking Best Practices

Andrew Brooks, Ph.D., Chief Operating OfficerCOO and Director, of Technology Development, Technology, RUCDR Infinite Biologics

The Challenges of Developing and Implementing Biospecimen Evidence-Based Practices

Helen Moore, Ph.D., Program Director, Biorepositories & Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

Practical Approaches to Expanding Biorepository Representation: Innovative Tissue Print Technologies for Collecting High Quality Snap-Frozen Specimens for Biomarker Research

Sandra M. Gaston, Ph.D., Director, Molecular Biomarkers Research Laboratory, Department of Pathology and Laboratory Medicine, Tufts Medical Center Assistant Professor of Pathology, Tufts University School of Medicine

Managing Quality in Biorepository Operations to Support Translational Research- Experiences of the OHSU Knight BioLibrary

Devon Kelly, Director, OHSU Knight BioLibrary, Knight Cancer Institute, Oregon Health and Science University


Extending The Reach Of Molecular Diagnostics: Sample-To-Result Infectious Disease Tests

Barry Lutz, Ph.D., Research Assistant Professor, Department of Bioengineering, University of Washington


Antibody Validation to Prevent Error

David L. Rimm, M.D., Ph.D., Professor, Pathology; Executive Director, Translational Pathology; Director, Yale Pathology Tissue Services, Yale University

For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5496

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431



  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:


Jackson Laboratory - small logo 

Leica Biosystems 




Thomson Reuters-Large 

Local Partners:



City of SSF